Follow us on Twitter
twitter icon@FreshPatents

Platelet patents

Bulk PDF Downloads
      

This page is updated frequently with new Platelet-related patent applications.




new patent Medical device in particular for the separation of a fluid
A medical device for separating a fluid, in particular for separating platelet-rich plasma from whole blood, includes three containers and at least one corresponding connection line having an intermediate bifurcation. Provided on the connection line are valve means for enabling or preventing a flow of fluid.
Eltek S.p.a.


Dispersions for nanoplatelets of graphene-like materials and methods for preparing and using same
A dispersion of nanoplatelet graphene-like material, such as graphene nanoplatelets, in a solid or liquid dispersion media wherein the nanoplatelet graphene-like material is dispersed substantially uniformly in the dispersion media with a graphene-like material dispersant. Such dispersions may be used to prepare articles by three-dimensional (3d) printing, as well as to provide electrically conductive inks and coatings, chemical sensors and biosensors, electrodes, energy storage devices, solar cells, etc.
Graphene 3d Lab Inc.


Diagnostic methods for par4 antagonist therapy
The disclosure provides methods for identifying a par4 agonist responder or a par4 antagonist responder comprising contacting a par4 agonist with platelets in a sample obtained from a subject in need thereof. The methods also include administering a par4 antagonist to the subject identified as a par4 agonist responder or a par4 antagonist responder.
Cambridge Enterprise Limited


Fluidic device for producing platelets
The invention relates to a fluidic device for producing platelets from a suspension of megakaryocytes or their fragments, comprising a production chamber comprising at least one channel in which a suspension of megakaryocytes is introduced to flow from its inlet to its outlet wherein said channel is textured with a plurality of obstacles on at least one portion of its inner surface. The invention is further directed to an ex vivo method for producing platelets from megakaryocytes using a fluidic device as defined above..
Espci Paristech


Targeting tissue factor to activated platelets
The current invention relates to procoagulant fusion proteins, polynucleotides that encode said fusion proteins and cells that expresses said fusion proteins. Furthermore, the current invention relates to fusion proteins for use as a medicament.
Novo Nordisk A/s


Functionalized microgels with fibrin binding elements
Ultra-low crosslinked microgels made of an ultra-low crosslinked polymer are provided. The microgels, also referred to as platelet-like particles (plps), preferably have <0.5% crosslinking densities.
Georgia Tech Research Corporation


Compositions comprising lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity
A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (nsaids) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a nsaid-containing formulation that possess low gastrointestinal (gi) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulstion for internal, oral, direct or topical administration..
The Board Of Regents Of The University Of Texas System


Systems, compositions, and methods for transplantation and treating conditions
Systems and methods for purification and concentration of autologous alpha-2 macroglobulin (a2m) from whole blood and or recombinant a2m are provided. Also provided are methods of treating wounds with a2m.
Cytonics Corporation


Method of preparing solution containing stem cells
A method of preparing a stem-cell containing solution includes: (1) storing a mixture of a blood sample and a divalent cation chelating agent at a temperature between 2 and 12 degrees celsius for a period of from 3 hours to 72 hours so as to have the mixture with two or more separate layers, wherein a liquid in one of the separate layers contains platelets and stem cells; (2) collecting the liquid into a container; (3) centrifuging the liquid in the container until multiple particles suspended in the liquid are deposited at a bottom of the container, wherein the particles contain the stem cells and the platelets; and (4) re-suspending the particles in a buffer or liquid.. .
Stembios Technologies, Inc.


Methods of preventing platelet alloimmunization and alloimmune platelet refractoriness and induction of tolerance in transfused recipients
Methods and compositions for the prevention or reduction of platelet transfusion associated complications are provided. Methods are provided to modify donor whole blood or platelets prior to transfusion to prevent or reduce alloimmune platelet refractoriness..
Bloodworks


Methods of prevention or treatment for pathologic thrombosis or inflammation


The present disclosure relates to methods of affecting platelet activation by the use of a pc-tp inhibitor. The pc-tp inhibitor can be administered to a subject in need thereof in order to prevent or treat pathologic thrombosis, or to treat a disorder treatable by a par4 inhibitor..
Thomas Jefferson University


Sample preparation analysis of platelet proteins


The present invention provides a novel method of in vitro sample preparation for the analysis of proteins. In a first aspect, the present invention is a method comprising the separation and individual treatment of blood platelets and platelet-poor plasma obtained from a platelet-rich plasma sample.
Randox Laboratories Ltd


Component parts produced by thermoplastic processing of polymer/boron nitride compounds, polymer/boron nitride compounds for producing such component parts, producing such component parts and use thereof


The invention relates to a method for producing a component part having a wall thickness of at most 3 mm on at least one part of the component part, comprising the method step of injection molding by means of an injection mold in an injection molding machine using a polymer/boron nitride compound, wherein the polymer/boron nitride compound comprises a thermoplastically processable polymer material and a heat-conducting filler, wherein the filler comprises platelet-shaped hexagonal boron nitride particles and wherein the injection rate during injection-molding is at most 200 mm/s. The invention further relates to a component part produced using such a method and a polymer/boron nitride compound for producing such a component part.
3m Innovative Properties Company


Coagulation factor-targeting to tlt-1 on activated platelets


The current invention relates to: procoagulant proteins which may, for example, be fusion proteins or chemical conjugates; methods of producing said procoagulant proteins; polynucleotides that encode said fusion proteins and cells that expresses them. Furthermore, the current invention relates to procoagulant proteins for use as a medicament.
Novo Nordisk A/s


Method for obtaining a cytokine-rich composition and composition obtained by means of this method


The invention relates to a method for preparing serums, said serums comprising cytokines and coagulation factors, and for preparing fibrin gel compositions, wherein the method comprises submitting an isolated biological sample comprising platelets and/or leukocytes to different steps of different gravity force to obtain supernatants with high concentrations of cytokines and coagulation factors. The invention also encompasses serums obtainable by this method, and other derived products comprising them.
Nte-sener Healthcare, S.a.


Application and pharmaceutical composition of preactivated and disaggregated shape-changed platelets


Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×106 to 1×108. Sc-plt is a disaggregated and activated platelet, the secretome from platelet activation has been deprived after sc-plt preparation but their membrane still preserve cell adhesion molecular and integrin glycoprotein (eg.

Bar compositions comprising platelet zinc pyrithione


Antimicrobial bar compositions can include, for example, from about 0.1% to about 35%, by weight of the antimicrobial bar composition, of water; from about 45% to about 99%, by weight of the antimicrobial bar composition, of soap; and from about 0.01% to about 5%, by weight of the antimicrobial bar composition, of platelet zinc pyrithione (“platelet zpt”). The platelet zpt includes a median particle diameter of about 2 microns to about 3 microns, a mean particle diameter of about 3 microns to about 4 microns, and a thickness of about 0.6 microns to about 15 microns..
The Procter & Gamble Company


Extracellular mitochondrial components for detecting inflammatory reactions and conditions


The present disclosure highlights the relationship between extracellular mitochondrial components, optionally in combination with the secreted phospholipase a2-iia and/or an auto-antibody, and in vivo as well as in vitro and inflammatory reactions/conditions, especially those released as a result of the degradation of a platelet. The present disclosure provides methods for determining the presence of inflammatory mediators, for limiting inflammatory reactions/conditions, for the diagnosis inflammatory reactions/conditions, for screening therapeutics for the treatment and/or the alleviation of symptoms of inflammatory reactions/conditions based on the detection or modulation of the level of these extracellular mitochondrial components..
University Of Washington


Process of dry milling particulate materials


Graphene platelet nano composites with metal or metal oxides. The coated and composited particles are useful as electrodes and for electrical applications..

System, method and kit for the collection and processing of amniotic fluid and placental aspirate


Disclosed is a system for the collection, processing and reuse of amniotic fluid and placental aspirate at a c-section site. The system includes a canister positioned along the vacuum line through which the amniotic fluid and placental aspirate is suctioned.
Bioexcell, Inc.


A therapeutic agent delivery arteries


A delivery system for delivery of a therapeutic agent such as stem cells into a vein and across a micro circulation system into an artery comprises a multi lumen catheter for delivery of a therapeutic agent. A discharge device is located in a vein.
Tulip Endovascular Innovation Limited


Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof


This invention relates generally to monoclonal antibodies that recognize cd47, more specifically to cd47 antibodies that do not cause a significant level of agglutination of cells, red blood cell depletion, anemia, and/or platelet depletion, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.. .
Inhibrx Llc


Targeted delivery of factor viii proteins to platelets


The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human factor viii or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.. .
Novo Nordisk A/s


Ceramic lamellar composites


Disclosed herein is a method of: placing between a cooling element and an opposing surface a slurry of: a dielectric powder containing barium titanate, a dispersant, a binder, and water; maintaining the cooling element at a temperature below the opposing surface to cause the formation of ice platelets perpendicular to the surface of the cooling element and having the powder between the platelets; subliming the ice platelets to create voids; sintering the powder to form the dielectric material; and filling the voids with the polymeric material. The process can produce a composite having: a sintered dielectric material of barium titanate and platelets of a polymeric material embedded in the dielectric material.
The Government Of The United States Of America, As Represented By The Secretary Of The Navy


Methods and devices for obtaining and providing combination cell therapy


The invention is directed to a therapeutic composition that includes a first cell preparation that includes isolated stromal cells of a first type and a second cell preparation that includes isolated stromal cells of a second type. The first and second cell preparations may include cultured cells.
Spinesmith Partners, L.p.


Platelet-type zirconium phosphate and preparing same


A platelet-type zirconium phosphate, which has a p—oh group contained in a structure thereof, and has a crystalline peak at a 2θ value of 11.6±2 degrees and no crystalline peak at a 2θ value of less than 11.6±2 degrees in x-ray diffraction analysis, is provided. The platelet-type zirconium phosphate has a platelet-type structure and can be uniformly dispersed at a nanoscale level in a coating film to exhibit excellent surface gloss and barrier capability.
Posco


Method of inhibiting complement activation with human anti-factor c3 antibodies and uses thereof


A method of inhibiting complement activation mediated by c3b inhibitors in a subject includes administering a c3b inhibitor to the subject to inhibit at least one of c3b binding to factors b and properdin, inhibit c3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of c3a, c5a, and mac.. .
Novelmed Therapeutics, Inc.


Blood withdrawal device


The invention relates to a blood withdrawal device (10) having an active liquid (12) containing a platelet aggregation inhibitor, a microneedle patch (14) having a plurality of microneedles (20), wherein a plurality of microneedles (20) is configured for dispensing the active liquid (12) into the skin (34) of a patient, and comprising a negative pressure generating device (16) connected to a plurality of microneedles (20) such that blood (46) can be drawn from the skin (34) by means of the microneedles (20). According to the invention the active liquid (12) contains a pain killer, the active liquid (12) is arranged in the blood receptacle (18), and the negative pressure generating device (16) is connected to the blood receptacle (18), such that by generating an excess pressure in the blood receptacle (18), the active liquid (12) can be dispensed by way of microneedles (20), and by generating a negative pressure, blood (46) can be drawn into the blood receptacle (18)..

Surge protection device, comprising at least one surge arrester and one thermally trippable switching device connected in series with the surge arrester


The invention relates to a surge protection device, comprising at least one surge arrester and one thermally trippable switching device connected in series with the surge arrester, wherein the above-mentioned means form a structural unit and the thermal tripping means is arranged in the region in which heating of the surge arrester is to be expected on overloading thereof. The thermal tripping means is in the form of a stop part through which there is no operating or surge current flowing and which effects or enables unlatching of the switching device in the case of thermal overload.
Dehn + SÖhne Gmbh + Co. Kg


Sensing element compositions and sensor system for detecting and monitoring structures for hydrocarbons


Carbon nanotubes, graphene nanoplatelets, and/or metal oxides are incorporated in a polymer to form a sensing element that may be applied on to a surface for sensing hydrocarbon leakage, mechanical stress, and/or temperature change of a hydrocarbon transportation and/or storage structure. Electrical signals from the sensing element are processed to check for indicators of leakage, stress and/or temperature change..
1835963 Alberta Ltd.


Plastics composition comprising at least one metal pigment, production and use thereof


The present invention relates to a plastics composition which comprises at least one platelet-shaped metal pigment from a range of from 0.01 to 25 wt.-%, at least one light stabilizer from a range of from 0.01 to 10 wt.-% and at least one antioxidant from a range of from 0.01 to 2 wt.-%, in each case relative to the proportion by weight of the plastics composition.. .
Eckart Gmbh


Silk/platelet composition and use thereof


The present disclosure relates generally to silk fibroin and unlysed platelet compositions. The compositions are useful for a variety of medical uses such as wound healing or repair and soft tissue repair or augmentation..
Tufts University


Formulation, apparatus, and methods for treatment of brain trauma


A formulation comprising platelet rich plasma (prp) for treatment of patients who have experienced brain injury, consisting of a mixture of human autologous plasma, d5w, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity.

Method of detection of platelet-activating antibodies that cause heparin-induced thrombocytopenia/thrombosis


The present invention provides a method of detecting platelet activation in a patient, the method comprising the steps of a) obtaining a blood sample from a patient suspected of having heparin-induced thrombo-cytopenia (hit); b) incubating an effective amount of platelet factor 4 (pf4) with a sample of platelets to yield a sample of pf4-treated platelets; c) contacting the patient blood sample with the pf4-treated platelets; and d) measuring the extent of platelet activation, wherein an increase in platelet activation compared with results obtained using a normal blood sample is indicative of the patient having hit.. .
Blood Center Research Foundation


Factors


A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of platelets and haemoglobin in a sample from the cancer patient, and (b) comparing the level of platelets in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of platelets and higher level of haemoglobin in the sample correlates with increased benefit to the patient.. .
Oxford Biomedica (uk) Limited


Rigidized fiber array


A composite component includes a fiber array, a plurality of platelets bridging between fiber filaments of the fiber array and rigidizing the fiber array, and a resin-based phase disposed within voids of the fiber array. A method of making a composite component is also disclosed..
United Technologies Corporation


Medical devices containing rapamycin analogs


A medical device comprises a supporting structure capable of containing or supporting a pharmaceutically acceptable carrier or excipient, which carrier or excipient may contain one or more therapeutic agents or substances, with the carrier preferably including a coating on the surface thereof, and the coating containing the therapeutic substances, such as, for example, drugs. Supporting structures for the medical devices that are suitable for use in this invention include, but are not limited to, coronary stents, peripheral stents, catheters, arterio-venous grafts, by-pass grafts, and drug delivery balloons used in the vasculature.
Abbott Laboratories


Compositions comprising lecithin oils and nsaids for protecting the gastrointestinal tract and providing enhanced therapeutic activity


A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (nsaids) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a nsaid-containing formulation that possess low gastrointestinal (gi) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration..
The Board Of Regents Of The University Of Texas System


Extracts of curcuma amada and uses thereof


The invention concerns carbon dioxide extracts of curcuma amada (mango ginger), including supercritical carbon dioxide extracts of c. Amada; methods for their production; compositions comprising the extracts; methods for treating or delaying the onset of conditions such as cell proliferation disorder (e.g., cancer), inflammation, infection, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hyperglycemia, platelet hyper-aggregation, immune disorder such as autoimmune disorder, or neurodegenerative condition; and methods for inhibiting expression of bcl-2, bak, and p53 genes; inhibiting expression of the cox-2 and nf-kb genes, inhibiting production of phosphorylated target of rapamycin (tor), modulating amp-activated protein kinase (ampk), inhibiting protein kinase b (akt) signaling, modulating the ras/raf/mek/erk signaling pathway, and modulating the ras/pi3k/pten/akt/mtor signaling pathway.
Flavex Naturextrakte Gmbh


Method and device for determining the orientation of pigment particles over an extended region of an optically effect layer


The present invention relates to the field of the protection of security documents and more particularly to a method and a device for determining the distribution and orientation of platelet-shaped pigment particles over an extended region of an optical effect layer (oel). The method described herein comprises the steps of a) taking at least one image, under illumination of said extended region of the optical effect layer with collimated light incident from at least one first direction, of reflected light of said extended region of the optical effect layer from at least one second direction, using a telecentric lens-and-camera assembly having the optical axis of the telecentric lens oriented along said second direction, and b) processing the at least one image of said extended region to extract quantitative particle distribution and orientation information.
Sicpa Holding Sa


Conductive ink composition and conductive architecture for wireless antenna


A conductive ink composition for the wireless antenna with adhesion enhancement by carbon flakes that aims to enormously reduce the solid content of conductor and can be used to print antennas. For example, silver content of the ink composition is greatly decreased due to the absence of insulated binder.

Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use


The invention relates to glycoprotein vi (gpvi), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of gpvi, preferably recombinant gpvi, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases.
Sanofi-aventis Deutschland Gmbh


Cross-linked platelet material


This document provides methods and materials involved in making and using cross-linked platelet material (e.g., cross-linked lysate material from human platelets such as human platelets obtained from platelet blood collection preparations or platelet apheresis preparations). For example, methods and materials for cross-linking platelet material (e.g., lysate material obtained from human platelets) to form a matrix (e.g.
Mayo Foundation For Medical Education And Research


Compositions and minimally invasive methods for treating incomplete tissue repair


Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to bone tissue particularly a vertebral body or in combination with a bone graft are disclosed..

Methods for the repair and rejuvenation of tissues using platelet-rich plasma compositions


This application relates to cosmetic methods for improving skin conditions. The methods generally include the administration of platelet-rich plasma and cultured autologous cells to a subject after a micro-needling procedure has been performed.

Activated platelet preservation composition, preserving activated platelet and preserved activated platelet using the same


The present invention relates to an activated platelet preservation composition, a method for preserving activated platelet and a preserved activated platelet using the same. Here, the inventive feature relates to an activated platelet preservation composition comprising a divalent cation, chloride, vitamin b, a selenium source and a solvent, a kit using the same, a method for preserving an activated platelet, and a preserved activated platelet using the same.

Thienopiperidine derivative and use thereof


The present invention also relates to the uses of the described thienopiperidine derivative in preparing drugs for preventing platelet aggregation and for treating or preventing cardiovascular and cerebrovascular diseases.. .

Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same


The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.. .
The Medicine Company


Factors


A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of haematocrit and haemoglobin in a sample from the cancer patient, and (b) comparing the level of haematocrit in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of haematocrit and higher level of haemoglobin in the sample correlates with increased benefit to the patient.. .
Oxford Biomedica (uk) Limited


Graphene-augmented composite materials


Composite materials are augmented with functionalized graphene having added amine groups, benzoxazine groups, imide groups, or a combination of amine groups and imide groups on a surface of the graphene, epoxide groups formed on at least one edge of the graphene and/or holes formed through the graphene. The functionalized graphene is integrated into a composite material as a supplement to or as a replacement for either the carbon reinforcement material or the resin matrix material to increase strength of the composite materials, and may be in the form of a functionalized graphene nanoplatelet, a flat graphene sheet or film, or a rolled or twisted graphene sheet or film..
The Boeing Company


Graphene-augmented composite materials


Composite materials having carbon reinforcement fibers impregnated with a matrix material are augmented with functionalized graphene nanoplatelets having amine groups formed on a surface of the graphene nanoplatelets and epoxide groups formed on at least one edge of the graphene nanoplatelets as a supplement to or a replacement for resin matrix material to increase strength of the composite materials. Related methods of increasing strength of composite materials include mixing the functionalized graphene nanoplatelets into the matrix material prior to impregnating the carbon reinforcement fibers, depositing the functionalized graphene nanoplatelets onto the matrix material to form an interlayer, and depositing the functionalized graphene nanoplatelets onto a bed of carbon reinforcement fibers with no resin matrix material.
The Boeing Company


Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha


The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (nsclc) in which platelet-derived growth factor receptor alpha (pdgfrα) is expressed and is driving the disease, and provides methods for identifying a mammalian nsclc tumor that belongs to a subset of nsclc tumors in which pdgfrα is expressed, and for identifying a nsclc tumor that is likely to respond to a pdgfrα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian nsclc tumor in which pdgfrα is expressed, and for determining whether a compound inhibits the progression of a pdgfrα-expressing mammalian nsclc tumor..
Cell Signaling Technology, Inc.


Dynamic appearance-changing optical devices (dacod) printed in a shaped magnetic field including printable fresnel structures


A printed image is disclosed wherein the image may be in the form of an array of magnetically aligned platelets or flakes that may by uniform in shape and size and wherein the flakes are arranged in a particularly manner to form optically illusive images useful as security devices, or useful in beam steering applications. In one embodiment of this invention printed array is disclosed a plurality of concentric rings of magnetically aligned platelets disposed upon a substrate in the form of a fresnel structure, preferably a fresnel reflector.

Flame retardant composition comprising graphene nanoplatelets


The composition has optimal flame retardant properties even when applied in relatively modest quantities.. .

Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries


The invention provides compositions and methods for treatment of tendon and ligament injuries and/or repair of damaged tendons and ligament. The invention provides compositions comprising a biocompatible matrix and platelet-derived growth factor (pdgf)..

Method for producing megakaryocytes, platelets and/or thrombopoietin using mesenchymal cells


Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing tpo simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture.

Novel hydroximic acid derivative and medical application thereof


The present invention relates to a kind of new hydroximic acid derivatives, in particular, hydroximic acid derivatives of pyrazolopyrimidine and their medical applications, which have inhibition to histone deacetylase 1 and two kinds of tyrosine kinases (vascular endothelial cell growth factor receptors as well as platelet-derived growth factor receptors) simultaneously, and thus can be used for treatment of diseases related to those three kinds of enzymes. This kind of compounds both exerts a synergistic effect sufficiently to increase biological activity, and avoids problems caused by different properties and metabolisms, therefore is more practical and has good prospects..

Method of treatment using an association of losartan and acetylsalicylic acid, and kit


The present invention relates to a method of treatment comprising administering an association of an antihypertensive agent and antiplatelet agent, wherein the antihypertensive agent is administered daily and the antiplatelet agent is administered every three days. The invention further comprises a kit comprising the association of the antihypertensive agent and the antiplatelet agent, packed so as to facilitate the compliance and the correct administration of the dosage of treatment by the patient..

Biochemical markers of platelet storage


Compositions and methods determines post-transfusion survival of platelets and the suitability of platelet units for transfusion by measuring the levels of one or more markers in a platelet sample. A method determines post-transfusion survival of platelets (pl t) prior to transfusion, the method comprising the steps of: a) measuring the levels of one or more markers in a pl t sample selected from the group consisting of adenine, 13-hode/9-hode, caprylate, laurate, c-glycosyltryptophan, andro steroid monsulfate 2, and unelucidated compounds (uc) 1-4; b) comparing the level of the one or more markers in the plt sample with the level of the one or more markers present in a control sample, wherein a higher or lower level of the one or more markers in the pl t sample is indicative of post-transfusion survival of platelets..
Puget Sound Blood Center


Production of graphene and graphane


The present invention provides a method for the production in an electrochemical cell of one or more of graphene, graphite nanoplatelet structures having a thickness of less than 100 nm, and graphane, wherein the cell comprises: (a) a negative electrode which is graphitic; (b) a positive electrode which may be graphitic or another material; and (c) an electrolyte selected from (i) an ionic liquid; (ii) a deep eutectic solvent; and (iii) a solid ionic conductor, optionally further comprising (iv) one or more ionic species, wherein the amount of (i), (ii) or (iii) and (iv) is greater than 50 wt % based on the total weight of the electrolyte; and wherein the electrolyte includes a mixture of different cations; and wherein the method comprises the step of passing a current through the cell to intercalate ions into the graphitic negative electrode so as to exfoliate the graphitic negative electrode.. .
The University Of Manchester


Composition for maintaining platelet function


Provided is a composition for maintaining a function of platelets, having as an active ingredient a pyridone derivative represented by the following general formula (i), or a salt thereof (in the formula, ring a, r1, r2, r3, and r4 represent the definitions given in the description).. .
Kyoto University


Method for machining a casing of an aircraft turboshaft engine and scraper tool for implementing said method


A scraper tool for deburring an edge of an aircraft turboshaft engine casing is arranged to be mounted in a milling device. The scraper tool includes a body including, on a first end, a connection for the milling device and, on a second end, a deburring module including a turning lathe platelet including at least one cutting edge arranged so as to deburr the casing edge.
Snecma


Implantable sealable member with mesh layer


The provided technologies provide an implant closure device having a mesh layer formed on a flexible substrate, collectively forming a sealable member, that improves a seal formed over an aperture in a body lumen. The mesh facilitates a faster and more secure adherence of the sealable member to the surrounding edges at the puncture site.
Vivasure Medical Limited


Automated platelet function analyzer and its analytical methods


An automated platelet function analyzer includes a sampling vessel, a preparation vessel, an analysis vessel, a sampling needle, a blood sample syringe, an analysis solution syringe, and a blood mixing device. A method for platelet analysis is also disclosed..
Sinnowa Medical Science & Technology Co., Ltd.


Method for diagnosing neuro-degenerative disease


A method for the diagnosis of alzheimer's disease (ad) or parkinson's disease (pd), including measuring the level of expression of one or more ad markers (table 1) or pd markers (table 2) in a sample of platelets isolated from a person suspected of having ad or pd, and determining whether the levels of expression are altered compared to a control.. .
Randox Laboratories, Ltd., Co. Antrim, United Kingdom


Automated platelet function analyzer and its analytical methods


An automated platelet function analyzer includes a sampling vessel, a preparation vessel, an analysis vessel, a sampling needle, an analysis solution syringe, a detergent syringe, and blood mixing devices. The sampling vessel is placed in a sample holder, which vacillates left and right.
Sinnowa Medical Science & Technology Co., Ltd.


Process for preparation of indolizine based derivatives as potential phosphodiestrase 3 (pde3) inhibitors


The present invention provides compounds of general formula 1 useful as potential phosphodiesterase3 (pde3) inhibitory agents and a process for the preparation thereof. The derivatives of formula 1 can be employed as therapeutics in human and veterinary medicine, where they can be used, for example, for the treatment and prophylaxis of the following diseases: heart failure, dilated cardiomyopathy, platelet inhibitors, cancer and obstructive pulmonary diseases..
Council Of Scientific & Industrial Research


Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo


The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinasons preparations for use in tissue regeneration and bone regeneration and pain reduction..

Compositions and methods for preserving donated blood


Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets..
Rythrx Therapeutics, Llc


System and collecting platelets and anticipating plasma return


A blood processing system for collecting plasma reduced platelets and anticipating plasma return includes a venous access device, a blood component separation device, a first return line, a recirculation line, and a second return line. The venous access device draws whole blood from a subject and returns blood components to the subject using a first pump.
Haemonetics Corporation


S isomers of alpha-methyl-hydrocinnamic acid for the treatment of blood disorders


The present intervention generally relates to compositions comprising s-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising s-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an s-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets.

Measuring antiplatelet activity


Provided herein are methods and materials for assessing platelet activity and/or the ability of substances (e.g., small molecule compounds and compositions comprising the same) to inhibit or activate platelet activity. For example, this document provides methods and materials that can include (a) applying abnormal flow conditions (e.g., oscillatory shear stress) to a sample of platelets (e.g., a blood sample or platelet-rich plasma sample) to stimulate the platelets, and (b) assessing the activity of the platelets.
Melaleuca, Inc.


Platelet protection solution having a beta-galactosidase inhibitor


The present invention relates to a platelet protection solution (pps) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of pps components that include a salt, a citrate source, a carbon source, or any combination thereof.. .
Velico Medical, Inc.


Method for manufacturing graphene platelets


A method for manufacturing graphene platelets includes the following steps of: providing a plurality of graphite blocks each including a plurality of stacked graphene layers, between every two graphene layers being a bonding formed by a van der waals force; applying a shear airflow produced by an airflow interface formed between a first flow path and a second flow path by a forward airflow and reverse airflow to the graphite block, the shear airflow having an energy sufficient for damaging the van der waals force to disengage a part of the graphene layers; and collecting a plurality of pieces of the graphene platelets, the graphene platelets including one or multiple of the graphene layers. Thus, the shear airflow of the present invention disengages the graphene layers from the graphite block to form the graphene platelets, thereby providing a simple manufacturing process and promoting mass production at a fast speed..
Taiwan Carbon Nanotube Technology Corporation


Chiral 1-(4-methylphenylmethyl)-5-oxo--pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion


Chiral 1-(4-methylphenylmethyl)-5-oxo-{n-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion. The present invention provides chiral (2s)-1-(4-methyl-phenylmethyl)-5-oxo-(3s)-{n-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2s)-1-(4-methylphenylmethyl)-5-oxo-(3r)-{n-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively.
Council Of Scientific & Industrial Research


Platelet protection solution having beta-galactosidase and sialidase inhibitors


The present invention relates to a platelet protection solution (pps) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of pps components that include a salt, a citrate source, a carbon source, or any combination thereof.. .
The Brigham And Women's Hospital, Inc.


Method to bioengineer designer platelets using gene editing and stem cell methodologies


A method of creating cells expressing specific platelet alloantigens is disclosed. In one embodiment, the method comprises the steps of (a) combining one or more guide rnas targeting within a platelet alloantigen target locus; (b) adding a repair template comprising a mutation in the target locus flanked by a homology arm on each side, wherein the template may additionally include a diagnostic restriction enzyme site at the target locus; (c) ligating the guide sequence of step (b) into a plasmid which also expresses a nuclease and, optionally, a selectable marker or a reporter gene; (d) transfecting pluripotent cells with the plasmid of step (c) in the presence of an hdr repair oligo; (e) cloning and testing the resulting reporter positive clones for expression of the alloantigen target of interest; and (f) culturing the resulting cells to expand their numbers or to create a differentiated cell type of interest..
Bloodcenter Research Foundaton


Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi


The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (pet) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body.
Piramal Imaging Sa


Prodrugs of anti-platelet agents


The invention relates to the compounds of formula ii, formula ia, formula iia or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula ii, formula ia, formula iia and methods for treating or preventing atherothrombosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Cellix Bio Private Limited


Compositions and methods for treatment of cardiovascular disease


In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness.. .

Serum-free medium containing pdgf for ds cells


The problem to be solved by the present invention is to provide a serum-free medium suitable for culturing of ds cells. The present invention relates to a serum-free medium for culturing of ds cells containing platelet-derived growth factor (pdgf), or to a method for culturing of dermal sheath (ds) cells, using serum-free medium comprising pdgf..
Shiseido Company, Ltd.


Anti-pdgfr-beta antibodies and uses thereof


The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
Regeneron Pharmaceuticals, Inc.


Extemporaneous preparation of autologous fibrin


An autologous fibrin is prepared extemporaneously from either a full blood sample or a prepared sample of poor platelet plasma wherein the latter is subjected to a dedicated treatment and combined isolation process performed by a removable single-use device wherein blood or plasma components are separated and subsequently treated individually to be eventually combined by the user outside the system. The the system includes a platform and a removable single-use device both being designed to cooperate mechanically..
Avance Medical SÀrl


Compositions comprising collagen and prp for tissue regeneration


A composition of matter is disclosed which comprises crosslinked collagen, platelet rich plasma (prp) and an inorganic salt. Methods of generating same and uses thereof are also disclosed..
Collplant Ltd.


Systemic and local ex vivo gene therapy of the skeleton


Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (pdgf) b, and wherein the multipotent stem cells express a sufficient amount of pdgfb to increase bone mass and strength or bone fracture healing.
Loma Linda University


Method for inhibiting platelet aggregation


A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 μg/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 μg/kg/min, wherein the active drug is tirofiban or a salt thereof.. .
Medicure International Inc.


Electrochemical process for production of graphene


A process of producing graphene and/or graphite nanoplatelet structures by the electrochemical reduction of carbon oxide in an electrochemical cell is provided, wherein the cell includes (a) a negative electrode including a transition metal, transition metal-containing alloy, transition metal-containing oxide, transition metal containing ceramic, or a combination thereof; (b) a positive electrode; and (c) an electrolyte; wherein the process includes the step of passing a current between the electrodes in the presence of the carbon oxide.. .
The University Of Manchester


Coating compositions and coating products made therefrom


A coating composition and coating products made therefrom, containing modified inorganic nanoplatelets that form mesomorphic structure in a resin phase. The coating products exhibit low permeation/penetration properties, and can be used as anti-corrosion or barrier coatings..
Texas A&m University


Methods and systems for collecting mononuclear cells


A method for obtaining mncs is set forth. The method includes: separating mononuclear cells from a biological fluid that includes red blood cells, plasma and platelets and collecting a targeted number of mononuclear cells in a suspension including plasma and residual red blood cells and platelets; concentrating the separated mononuclear cells; removing plasma from the concentrated mononuclear cells until the amount of residual plasma remaining with the concentrated mononuclear cells reaches a pre-determined volume; and adding a crystalloid solution to the concentrated mononuclear cells.
Fenwal, Inc.


Methods for treating bleeding disorders using a platelet subpopulation


The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor vii (rfviia), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rfviia.. .
Baxalta Gmbh




Platelet topics:
  • Growth Factor
  • Fibroblast
  • Nanoparticle
  • Autologous
  • Leukocytes
  • Circulation
  • Transforming Growth Factor
  • Therapeutical
  • Platelet Derived Growth Factor
  • Bone Morphogenetic Protein
  • Endothelial
  • Recombinant
  • Stem Cells
  • Respiratory System
  • Dispensing System


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.


    4.196

    4580

    469770 - 0 - 101